Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri M A, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino R M, Labianca R, Gebbia N, Russo A
Department of Oncology, Section of Molecular Oncology, University of Palermo, Palermo Italy.
Ann Oncol. 2002 Sep;13(9):1438-46. doi: 10.1093/annonc/mdf226.
K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters.
Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for primary colorectal carcinoma, were prospectively studied for K-ras mutations by PCR/single strand conformation polymorphism sequencing.
Seventy-four of the 160 (46%) primary colorectal carcinomas presented mutations in K-ras: 54% in codon 12, 42% in codon 13 (particularly G-->A transition) and 4% in both. Codon 12 K-ras mutations were associated with mucinous histotype (P <0.01), while codon 13 K-ras mutations were associated with advanced Dukes' stage (P <0.05), lymph-node metastasis (P <0.05) and high S-phase fraction (P <0.05). Multivariate analysis showed that codon 13 K-ras mutations, but not any mutation, were independently related to risk of relapse or death.
Our results suggest that codon 12 K-ras mutations may have a role in the mucinous differentiation pathway, while codon 13 mutations have biological relevance in terms of colorectal cancer clinical outcome.
K-ras突变是在结直肠癌发生过程中最早观察到的事件之一,大多发生在密码子12和13,较少发生在密码子61,据估计这三个密码子对该蛋白的生物学活性都至关重要。然而,此类突变的预后意义仍存在争议。我们的目的是评估原发性结直肠癌中任何或特定的K-ras突变是否具有预后意义,并与临床病理参数相关。
对连续160例未经治疗的患者(中位随访71个月)进行前瞻性研究,这些患者因原发性结直肠癌接受切除手术,通过聚合酶链反应/单链构象多态性测序对配对的肿瘤和正常组织样本进行K-ras突变检测。
160例原发性结直肠癌中有74例(46%)出现K-ras突变:密码子12突变占54%,密码子13突变占42%(特别是G→A转换),两者同时突变占4%。密码子12的K-ras突变与黏液组织学类型相关(P<0.01),而密码子13的K-ras突变与Dukes分期晚期(P<0.05)、淋巴结转移(P<0.05)和高S期分数(P<0.05)相关。多变量分析显示,密码子13的K-ras突变而非任何突变与复发或死亡风险独立相关。
我们的结果表明,密码子12的K-ras突变可能在黏液分化途径中起作用,而密码子13的突变在结直肠癌临床结局方面具有生物学相关性。